Table 2 Characteristics of participants of patients, comorbidities, and reported side effects
Author/year | Characteristic of/comorbidity of patients | Characteristic of/comorbidity of patients | Discontinuations/reason |
|---|---|---|---|
Serap-Ekici et al. (2021), this study | 18 (54.6%) heavy autism 15 (45.4%) mild autism 3 (9%) epilepsy 7 (21%) abnormal EEG | Restlessness in 7 (22,5%) resolved after resolved after adjusting the dose, seizures increase in stereotypes | 2 (6%) seizures n=1 Increase in stereotypes n= 1 |
Aran et al. (2019) | 77% low intellectual disability 14 (23.3%) epilepsy | Any adverse event (51%), sleep disturbances (14%), restlessness (9%), nervousness (9%), loss of appetite (9%), gastrointestinal symptoms (7%), unexplained laugh (7%), mood changes (5%), fatigue (5%), nocturnal enuresis (3.5%), tremor (3.5%), sleepiness (2%), anxiety (2%), confusion (2%), psychotic event (2%) | 1 (1.6%) Severe psychotic events |
Lihi Bar-Lev Schleider et al. (2019) | 27 (14.4%) epilepsy Antipsychotics (56.9%), | Restlessness (6.6%), sleepiness (3.2%), psychoactive effect (3.2%), increased appetite (3.2%), digestion problems (3.2%), dry mouth (2.2%), lack of appetite (2.2%) | 23 (12.2%) no therapeutic effect and side effects, some patients intended to return to treatment again |
Paulo Fleury et al. (2019) | 5 (27.7%) epilepsy (46.7%) antipsychotics | Sleepiness, moderate irritability (n = 3); diarrhea, increased appetite, conjunctival hyperemia, and increased body temperature (n = 1) Nocturia (n = 2), which in one case, the heart rate increase, psycho-behavioral problems | 3 out of 18 (16.7%) psycho-behavioral effects and increased heart rate |
Barchel et al. (2019) | Atypical antipsychotics (58.4%), | Somnolence (22.6%), appetite decrease (11.3%), appetite increase (7.5%), insomnia (3.7%), sense abnormality response (to temperature) (3.7%), diarrhea (3.7%), hair loss (1.8%), nausea (1.8%), confusion (1.8%) | 5 (9.4%) |
Mostafavi and Gaitanis (2020) | (63%) developmental regression | Increases in OCD, repetitive behaviors, insomnia, mania (3 on Hemp oil, one on medical marijuana) | None |
69%) epilepsy (63%) developmental delay | Three patients reported mild adverse events (unspecified). | None | |
McVige et al. (2020) |